|
Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids |
|
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Uterine fibroids (also called leiomyomata or myomas) are benign tumors of the myometrium, the smooth muscle layer of the uterus. Most women develop fibroids. In the sixth decade of life, the prevalence of fibroids is almost 70% in Caucasian women and 80% in black women. In the United States, where the annual cost of hysterectomies exceeds $1.2 billion, fibroids are the most common indication for hysterectomy. About 25% of fibroids are symptomatic. They can produce pain, bleeding, infertility, abdominal enlargement, urinary frequency, constipation, and dyspareunia (pain during intercourse). Treatments for symptomatic fibroids include medical management, hysterectomy, myomectomy (removal of the fibroids while leaving the uterus in situ), radiofrequency ablation (RFA), uterine artery embolization (UAE), laser ablation, cryoablation, and image-guided thermal ablation. All current surgical treatments are invasive and all treatments have limitations. Indexing Status Subject indexing assigned by CRD MeSH Humans; Magnetic Resonance Imaging; Ultrasonic Therapy; Ultrasound, High-Intensity Focused, Transrectal; Uterine Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32014000491 Date abstract record published 07/04/2014 |
|
|
|